A Phase 1B/2 Randomized, Multicenter, Open-Label Study Of Iberdomide (CC-220) In Combination With Polatuzumab Vedotin Plus Rituximab Or Tafasitamab Or Rituximab Plus Chemotherapy For Subjects With Relapsed Or Refractory Aggressive B-Cell Lymphoma
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 发起方
- Celgene
- 试验地点
- 27
- 主要终点
- Recommended Phase 2 Dose (RP2D)
研究概览
简要总结
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based chemotherapy (Cohort C)) for participants with relapsed or refractory aggressive B-cell lymphoma (R/R a-BCL). All 3 cohorts will be open for enrollment at study start. Part 1 (dose escalation) will be followed by Part 2 (dose expansion), in which participants will be randomized to one of three cohorts, with CC-220 at the recommended Phase 2 Dose in combination with the Cohorts A, B and C treatment that is compared to their individual standard of care regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must satisfy the following criteria to be enrolled in the study:
- •Participant is ≥ 18 years of age at the time of signing the informed consent form (ICF).
- •Participant has histologically confirmed (per local evaluation) diagnosis of, aggressive B-cell lymphoma (a-BCL) according to 2016 WHO classification among the following subtypes:
- •Diffuse large B-cell lymphoma (DLBCL), Not otherwise specified (NOS) including Germinal center B-cell and Activated B-cell types;
- •High-grade B-cell lymphoma, with MYC and B-cell lymphoma 2 (BCL2) and/or B-cell lymphoma 6 (BCL6) rearrangements;
- •Primary mediastinal (thymic) large B-cell lymphoma (PMBCL);
- •Primary cutaneous DLBCL-leg type;
- •Anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma;
- •Epstein Barr virus positive (EBV+) DLBCL, NOS;
- •Grade 3b Follicular lymphoma (FL).
- •Participants must have relapsed or refractory disease after at least 2 prior lines of therapy including Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP)-like regimen OR after one prior line of standard therapy and being not eligible for autologous stem cell transplant (ASCT); participants previously treated with CAR-T therapy can be enrolled.
- •Participant must have measurable disease defined by at least one FDG-avid lesion for FDGavid-subtype and one bi-dimensionally measurable (> 1.5 cm in longest diameter) disease by computed tomography (CT) or magnetic resonance imaging (MRI), as defined by the Lugano classification (Cheson, 2014).
- •Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or
- •Participant must have the following laboratory values:
- •Absolute neutrophil count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without growth factor support for 7 days (14 days if pegylated granulocyte-colony stimulating factor (peg-G-CSF))
- •Hemoglobin ≥ 8 g/dL
- •Platelets ≥ 75 x 109/L or ≥ 50 x 109/L in case of documented bone marrow involvement (> 50% or tumor cells), without transfusion for 7 days
- •Aspartate aminotransferase / serum glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase / serum glutamic pyruvic transaminase (ALT/SGPT) ≤ 2.5 x ULN except in the case of documented liver involvement by lymphoma, where ALT/SGPT and AST/SGOT must be ≤ 5.0 x ULN.
- •Serum total bilirubin ≤ 2.0 mg/dL (34 μmol/L) except in cases of Gilbert syndrome, then ≤ 5.0 mg/dL (86 μmol/L)
- •Estimated serum creatinine clearance of ≥ 50 mL/minute using the modification of diet in renal disease formula.
- •All participants must:
- •Have an understanding that the study drug could have a potential teratogenic risk.
- •Agree to follow all requirements defined in the Pregnancy Prevention Program for CC-220 Pregnancy Prevention Plan for Participants in Clinical Trials.
- •A female of childbearing potential (FCBP) must:
- •a. Have two negative pregnancy tests as verified by the investigator prior to starting study therapy. She must agree to ongoing pregnancy testing during the course of the study, and after end of study therapy.
- •Male participants must:
- •Practice true abstinence (which must be reviewed on a monthly basis and source documented) or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study.
排除标准
- •The presence of any of the following will exclude a participant from enrollment:
- •Participant has any significant medical condition, active infection (including SARS-CoV-2 suspected or confirmed), laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
- •a. In the case of prior SARS-CoV-2 infection, symptoms must have completely resolved
- •Participant has any condition including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study.
- •Participant has any other subtype of lymphoma.
- •Participant has received systemic anti-cancer treatment, CAR-T or any T-cell targeting treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-220, whichever is shorter.
- •Participant has received prior therapy with a Cereblon-modulating drug (eg, lenalidomide, avadomide) ≤ 4 weeks prior to starting CC-
- •Participant has persistent diarrhea or malabsorption ≥ Grade 2 (NCI-CTCAE v5.0), despite medical management.
- •Participant has peripheral neuropathy ≥ Grade 2 (NCI CTCAE v5.0).
- •Participant is on chronic systemic immunosuppressive therapy or corticosteroids.
- •Participant has impaired cardiac function or clinically significant cardiac disease.
- •Participant had major surgery ≤ 2 weeks prior to starting CC-
- •Participant has known seropositivity for or active viral infection with human immunodeficiency virus (HIV).
- •Participant has known chronic active hepatitis B
- •Participant has history of other malignancy, unless being free of the disease for ≥ 3 years prior to starting study drug; exceptions to the ≥ 3-year time limit include history of the following:
- •Localized non-melanoma skin cancer
- •Carcinoma in situ of the cervix
- •Carcinoma in situ of the breast
- •Incidental histologic finding of prostate cancer (T1a or T1b as per Tumor Node Metastasis [TNM] staging system) or prostate cancer that has been treated with curative intent.
- •Participant has current treatment with strong CYP3A4/5 modulators.
- •Participant has known hypersensitivity to any component of planned combination medications in the regimen.
- •Participant has known allergy to thalidomide, pomalidomide, lenalidomide or avadomide.
研究组 & 干预措施
CC-220 + Polatuzumab vedotin + rituximab- Cohort A
Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
干预措施: CC-220 (Drug)
CC-220 + Polatuzumab vedotin + rituximab- Cohort A
Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
干预措施: Polatuzumab vedotin (Drug)
CC-220 + Polatuzumab vedotin + rituximab- Cohort A
Subjects with Relapsed or refractory (R/R) Aggressive B-cell lymphoma (a-BCL) will receive CC-220 at a dose specified by cohort dose level in combination with polatuzumab vedotin plus rituximab.
干预措施: Rituximab (Drug)
CC-220 + Tafasitamab- Cohort B
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
干预措施: CC-220 (Drug)
CC-220 + Tafasitamab- Cohort B
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with tafasitamab.
干预措施: Tafasitamab (Drug)
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
干预措施: CC-220 (Drug)
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
干预措施: Rituximab (Drug)
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
干预措施: Gemcitabine (Drug)
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
干预措施: Cisplatin (Drug)
CC-220 + Rituximab + Chemo (Cohort C)
Subjects with R/R a-BCL will receive CC-220 at a dose specified by cohort dose level in combination with rituximab plus chemotherapy (Gemcitabine, cisplatin, dexamethasone).
干预措施: Dexamethasone (Drug)
CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
干预措施: CC-220 (Drug)
CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
干预措施: Polatuzumab vedotin (Drug)
CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
干预措施: Rituximab (Drug)
CC-220 + Pola + Ritux vs Pola + Benda + Ritux (Cohort D)
Subjects will be randomized to receive either CC-220 + Pola (polatuzumab vedotin) + Ritux (rituximab) or polatuzumab vedotin + bendamustine + rituximab in 21-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study. Polatuzumab vedotin and rituximab will be administered at the same levels as in part 1. Bendamustine will be given to subjects randomized in the control arm at a dose of 90 mg/m2 IV on Days 1 and 2 of each of the first 6 cycles.
干预措施: Bendamustine (Drug)
CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E
Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
干预措施: CC-220 (Drug)
CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E
Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
干预措施: Tafasitamab (Drug)
CC-220 + tafasitamab vs Lenalidomide + Tafasitamab- Cohort E
Subjects will be randomized to receive either CC-220 + tafasitamab or lenalidomide + tafasitamab in 28-day treatment cycles. CC-220 will be given at the RP2D declared in Part 1 of this study and the tafasitamab will be at the same levels as in Part 1. Lenalidomide will be administered to subjects randomized in the control arm at a dose of 25 mg/day orally, for 21 days out of 28, for up to 12 cycles.
干预措施: Lenalidomide (Drug)
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
干预措施: CC-220 (Drug)
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
干预措施: Cisplatin (Drug)
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
干预措施: Rituximab (Drug)
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
干预措施: Gemcitabine (Drug)
CC-220 + Rituximab + Chemo vs Rituximab + Chemo (Cohort F)
Subjects will be randomized to receive either CC-220 + rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) or rituximab + chemotherapy (Gemcitabine, Cisplatin, Dexamethasone) in 21-day treatment cycles. CC-220 will be administered at the RP2D declared in Part 1 of this study and the combination medicines will be at the same levels as in part 1.
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Recommended Phase 2 Dose (RP2D)
时间窗: During the First cycle (each cycle is 28 days)
Frequency of dose limiting toxicities (DLT) to establish the RP2D of CC- 220 in combination with polatuzumab vedotin plus rituximab or tafasitamab or rituximab plus chemotherapy in subjects with R/R a-BCL.
Best Overall Response Rate (ORR)
时间窗: Up to 7 years
The proportion of participants with best overall response achieved during the study as either Complete Response or Partial Response before subsequent anti-lymphoma therapy.
Maximum Tolerated Dose (MTD)
时间窗: During the First cycle (each cycle is 28 days)
Frequency of dose limiting toxicities (DLT) to define MTD of CC- 220 in combination with polatuzumab vedotin plus rituximab or tafasitamab or rituximab plus chemotherapy in subjects with R/R a-BCL.
次要结局
- Incidence of Adverse Events (AEs)(From enrollment until at least 28 days after last dose of study treatment)
- Best ORR- Part 1(Up to 6 years)
- Complete Response Rate (CRR)- Part 2(Up to 7 years)
- Time to Response (TRR)- Part 2(Up to 7 years)
- Duration of Response (DOR)- Part 2(Up to 7 years)
- Progression-free Survival (PFS)- Part 2(Up to 7 years)
- Overall Survival (OS)- Part 2(Up to 7 years)
- Pharmacokinetics (PK) - Cmax(Up to 4 weeks)
- EORTC QLQ-C30 - Part 2(Up to 7 years)
- FACT-Lym LymS - Part 2(Up to 7 years)
- FACT/GOG-NTX-4 - Part 2(Up to 7 years)
- EQ-5D-5L - Part 2(Up to 7 years)